Metastatic breast cancer with double heterozygosity for the < em > BRCA1 < /em > and < em > BRCA2 < /em > genes responding to olaparib: A case report

In conclusion, the present study reported a female patient with double heterozygosity of BRCA1 and BRCA2 who benefited from olaparib monotherapy. Thus, olaparib may be a suitable treatment for such patients.PMID:38646498 | PMC:PMC11027096 | DOI:10.3892/ol.2024.14387

Source: Oncology Letters - April 22, 2024 Category: Cancer & Oncology Authors: Bin Shao Lijun Di Source Type: research